Literature DB >> 28745332

Impact of gender on outcome after chemoimmunotherapy in patients with chronic lymphocytic leukemia: a meta-analysis by the German CLL study group.

O Al-Sawaf1, S Robrecht1, J Bahlo1, A M Fink1, P Cramer1, J von Tresckow1, C Maurer1, M Bergmann2, T Seiler3, E Lange4, M Kneba5, S Stilgenbauer6, H Döhner6, M G Kiehl7, U Jäger8, C M Wendtner2, K Fischer1, V Goede1, M Hallek1, B Eichhorst1, G Hopfinger9.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 28745332     DOI： 10.1038/leu.2017.221

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  11 in total

1.  Clinical staging of chronic lymphocytic leukemia.

Authors:  K R Rai; A Sawitsky; E P Cronkite; A D Chanana; R N Levy; B S Pasternack
Journal:  Blood       Date:  1975-08       Impact factor: 22.113

2.  Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.

Authors:  M Hallek; K Fischer; G Fingerle-Rowson; A M Fink; R Busch; J Mayer; M Hensel; G Hopfinger; G Hess; U von Grünhagen; M Bergmann; J Catalano; P L Zinzani; F Caligaris-Cappio; J F Seymour; A Berrebi; U Jäger; B Cazin; M Trneny; A Westermann; C M Wendtner; B F Eichhorst; P Staib; A Bühler; D Winkler; T Zenz; S Böttcher; M Ritgen; M Mendila; M Kneba; H Döhner; S Stilgenbauer
Journal:  Lancet       Date:  2010-10-02       Impact factor: 79.321

3.  Suboptimal dosing of rituximab in male and female patients with DLBCL.

Authors:  Michael Pfreundschuh; Carsten Müller; Samira Zeynalova; Evelyn Kuhnt; Martin H J Wiesen; Gerhard Held; Tanja Rixecker; Viola Poeschel; Carsten Zwick; Marcel Reiser; Norbert Schmitz; Niels Murawski
Journal:  Blood       Date:  2013-12-02       Impact factor: 22.113

4.  The 158V polymorphism of Fc gamma receptor type IIIA in early rheumatoid arthritis: increased susceptibility and severity in male patients (the Swedish TIRA project).

Authors:  A Kastbom; A Ahmadi; P Söderkvist; T Skogh
Journal:  Rheumatology (Oxford)       Date:  2005-07-05       Impact factor: 7.580

5.  Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response.

Authors:  Ulrich Jäger; Michael Fridrik; Markus Zeitlinger; Daniel Heintel; Georg Hopfinger; Sonja Burgstaller; Christine Mannhalter; Wilhelm Oberaigner; Edit Porpaczy; Cathrin Skrabs; Christine Einberger; Johannes Drach; Markus Raderer; Alexander Gaiger; Monique Putman; Richard Greil
Journal:  Haematologica       Date:  2012-04-17       Impact factor: 9.941

6.  Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression.

Authors:  Vishal Lamba; Jatinder Lamba; Kazuto Yasuda; Stephen Strom; Julio Davila; Michael L Hancock; James D Fackenthal; Peter K Rogan; Barbara Ring; Steven A Wrighton; Erin G Schuetz
Journal:  J Pharmacol Exp Ther       Date:  2003-10-09       Impact factor: 4.030

7.  An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data.

Authors: 
Journal:  Lancet Oncol       Date:  2016-05-13       Impact factor: 41.316

8.  First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial.

Authors:  Barbara Eichhorst; Anna-Maria Fink; Jasmin Bahlo; Raymonde Busch; Gabor Kovacs; Christian Maurer; Elisabeth Lange; Hubert Köppler; Michael Kiehl; Martin Sökler; Rudolf Schlag; Ursula Vehling-Kaiser; Georg Köchling; Christoph Plöger; Michael Gregor; Torben Plesner; Marek Trneny; Kirsten Fischer; Harmut Döhner; Michael Kneba; Clemens-Martin Wendtner; Wolfram Klapper; Karl-Anton Kreuzer; Stephan Stilgenbauer; Sebastian Böttcher; Michael Hallek
Journal:  Lancet Oncol       Date:  2016-05-20       Impact factor: 41.316

9.  Population Pharmacokinetics of Obinutuzumab (GA101) in Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma and Exposure-Response in CLL.

Authors:  E Gibiansky; L Gibiansky; D J Carlile; C Jamois; V Buchheit; N Frey
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2014-10-29

10.  Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial.

Authors:  D Catovsky; S Richards; E Matutes; D Oscier; Mjs Dyer; R F Bezares; A R Pettitt; T Hamblin; D W Milligan; J A Child; M S Hamilton; C E Dearden; A G Smith; A G Bosanquet; Z Davis; V Brito-Babapulle; M Else; R Wade; P Hillmen
Journal:  Lancet       Date:  2007-07-21       Impact factor: 79.321
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.